MolMed: Dompé exercises the option right to undertake the market access and commercialization activities for Zalmoxis® in Switzerland, Turkey and Australia.

MolMed: Dompé exercises the option right to undertake the market access and commercialization activities for Zalmoxis® in Switzerland, Turkey and Australia.

Milan (Italy), February 8th 2018 - MolMed S.p.A. (MLMD.MI, "the Company"), medical biotechnology company focused on research, development, manufacturing and clinical validation of innovative therapies to treat cancer, announces that Dompé Farmaceutici S.p.A. ("Dompé") has exercised the right to develop and commercialize Zalmoxis® in Switzerland, Turkey and Australia, in accordance with the strategic commercialization and supply agreement of MolMed's proprietary therapy, signed with the Company and announced on July 26th 2017.

The option right, which corresponding value was already included in the agreement announced on July 26th, will allow to undertake the market access and commercialization activities in the above mentioned countries, including those aimed at obtaining marketing authorization and reimbursement price from the regulatory agencies, thus enlarging the addressable market of Zalmoxis®.

Zalmoxis®, MolMed's first patient-specific cell therapy, is devoted to the treatment of adult patients affected by leukaemia or other high-risk haematological malignancies, in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT).

Riccardo Palmisano, CEO of MolMed, commented: "Following the recent achievements related to the market access of Zalmoxis® in Italy and in Germany, we are pleased to announce the exercise of the option right for the commercialization in three new important markets as Switzerland, Turkey and Australia. This further step enable us to confirm the high potential of our cell therapy as well as the value of our partnership with Dompé".

"A further important step in the strategic alliance with MolMed that, benefitting from our shared distinctive and complementary competencies, enhances our commitment in providing innovative solutions to severe unmet clinical needs" commented Eugenio Aringhieri, CEO of Dompé "A partnership that allows us to continuously interact with the international scientific community with the aim of meeting the Patient's needs in additional territories".

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing FROM GENES TO THERAPY

Authorisation by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumours. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a novel therapeutic agent for solid tumours investigated in a broad clinical programme, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager MolMed S.p.A.

phone: [phone] e-mail:[e-mail]

Marcella Ruggiero

Press agent

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: [phone] mobile [phone] e-mail:[e-mail]

FROM GENES TO THERAPY